tbuckley/cabot-search huggingface dataset:
Simultaneous Use of Histone Deacetylase Inhibitor Valproic Acid Potentiates Natural Killer Cell Cytotoxicity against T-Lineage Acute Lymphoblastic Leukemia
Authors: Takayuki Takachi, Chihaya Imai, Yasushi Kasahara, Masaru Imamura, Makoto Uchiyama
Journal: Blood (2008)
Distribution of Radioactivity After Intravenous Administration of 7,12-Dimethylbenz[a]anthracene-7,12-C14 Into the Mouse2
Authors: Herbert I. Hadler, Katharine Lee
Journal: JNCI Journal of the National Cancer Institute (1960)

Journal Article Distribution of Radioactivity After Intravenous Administration of 7,12-Dimethylbenz[a]anthracene-7,12-C14 Into the Mouse Get access Herbert I. Hadler, Herbert I. Hadler Search for other works by this author on: Oxford Academic PubMed Google Scholar Katharine Lee Katharine Lee Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 25, Issue 4, October 1960, Pages 697–701, https://doi.org/10.1093/jnci/25.4.697 Published: 01 October 1960 Article history Received: 24 March 1960 Published: 01 October 1960
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
Authors: Andrés J M Ferreri, Marianna Sassone, Francesco Zaja, Alessandro Re, Michele Spina, Alice Di Rocco, Alberto Fabbri, Caterina Stelitano, Maurizio Frezzato, Chiara Rusconi, Renato Zambello, Suzana Couto, Yan Ren, Annalisa Arcari, Giovanni Bertoldero, Alessandro Nonis, Lydia Scarfò, Teresa Calimeri, Caterina Cecchetti, Marianna Chiozzotto, Silvia Govi, Maurilio Ponzoni
Journal: The Lancet Haematology (2017)
Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations
Authors: A.O. Siefker-Radtke, B. Mellado, K. Decaestecker, J.M. Burke, A. O'Hagan, A. Avadhani, B. Zhong, A. Santiago-Walker, P. De Porre, S. Brookman-May, J. Garcia-Donas
Journal: Annals of Oncology (2016)
STMC-17. N-CADHERIN UPREGULATION MEDIATES SLOW PROLIFERATION AND THERAPEUTIC RESISTANCE IN GLIOMA STEM CELLS
Authors: Satoru Osuka, Oltea Sampetrean, Nobuyuki Onishi, Hideyuki Saya, Erwin Van Meir
Journal: Neuro-Oncology (2016)

Glioblastoma is composed of heterogeneous tumor cell populations including those with stem cell properties and slow growth, termed glioma stem cells (GSCs). Slow growing tumor cells display reduced sensitivity to chemo- and radiotherapy and play an important role in tumor recurrence. However, the molecular mechanisms through which GSCs establish a state of slow growth are still unknown. Here, we examined the importance of cell-cell adhesion and N-cadherin expression in the slow growth of GSCs. We generated radioresistant GSCs by exposing Ink4A/Arf-/- neural stem cells with H-RasV12overexpressing to repeated cycles of irradiation (5Gy x 12). Acquisition of radioresistance was accompanied by a reduction in cell proliferation, an increase in cell-cell adhesion and a gradual upregulation of N-cadherin. To unravel the role of N-cadherin in radioresistance we modulated its expression in GSC through overexpression vectors and CRISPR/Cas9-mediated knockout. N-cadherin expression was associated with radio- and chemoresistance to temozolomide, reduced proliferation and reduced neural development. Mechanistically, we found that elevated N-cadherin expression led to the accumulation of β-catenin on the cell surface, resulting in the suppression of Wnt/ β-catenin signaling. To further validate our mice GSC findings in patients, we analyzed single cell RNA-seq analysis of human glioblastoma samples (GSE57872) and found that cells with high N-cad expression had low expression of cell cycle genes and high expression of stemness-related genes. In conclusion, our data indicate that increased N-cadherin expression induces a state of slow growth in GSCs through a reduction of Wnt/ β-catenin signaling, which underlies their therapeutic resistance. Therefore, N-cadherin represents a new important target to antagonize tumor recurrence in glioblastoma.
Predictive biomarkers to ramucirumab in Asian metastatic gastric cancer patients: Circulating angiogenic factors of VEGFR2 and neurophilin are predictive to ramucirumab efficacy in Asian recurrent/metastatic gastric cancer patients
Authors: S. Lim, S.J. Heo, T.S. Kim, H.J. Kwon, J.H. Kim, M.K. Jeong, H.S. Kim, S.H. Beom, H.C. Chung, S.Y. Rha
Journal: Annals of Oncology (2016)
Bone Marrow Stroma-Derived Mesenchymal Cell Cultures from Nude/Nude Rat Showing Both Ex Vivo Differentiation Properties and High Metastatic Potential in Nude Mice.
Authors: Mengyu Wang, Gunnar Kvalheim, Svein-Ole Mikalsen, Jahn M. Nesland, Gunhild Mælandsmo, Øystein Fodstad
Journal: Blood (2004)
Patterns of treatment and outcome of fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/Her2-negative (HER2-) metastatic breast cancer (MBC): a real life multicenter Italian experience
Authors: R. Palumbo, A. Ferzi, A. Gambaro, F. Sottotetti, L. Licata, C. Teragni, B. Tagliaferri, E. Pozzi, A. Bernardo
Journal: Annals of Oncology (2016)
Neuroendocrine carcinomas of the colorectal origin - Polish experience
Authors: A.D. Kolasin´ska-C´wikła, A. Lewczuk, A. Cichocki, K. Maciejkiewicz, E. Nowicka, K. Roszkowska-Purska, Z. Jodkiewicz, M. Tenderenda, J.B. C´wikła
Journal: Annals of Oncology (2016)
Ototoxicity in locally advanced head and neck cancer (LAHNC) patients (pts) treated with induction chemotherapy (IC) followed by cisplatin-based chemoradiotherapy (CRT)
Authors: C. Driessen, A. Snik, J. Leijendeckers, J.P. de Boer, H. Gelderblom, C. van Opstal, Wvan der Graaf, J. Kaanders, C. van Herpen
Journal: Annals of Oncology (2016)
High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis.
Authors: Emilia Cocorocchio, Fedro Peccatori, Simona Bassi, Federica Gigli, Davide Radice, Giancarlo Pruneri, Cristina Rabascio, Liliana Calabrese, Giovanni Martinelli
Journal: Blood (2005)
Breast cancer fast-track programme - Evolution and guidelines to prioritize patient referral
Authors: M.T.M. Martinez, I. Chirivella Gonzalez, K. Pinilla, A. Fernandez, A. Viala, A. Iranzo, A. Caballero, J. Calvete, A. Sanmartin, J. Navarro, B. Bermejo, A. Lluch-Hernandez
Journal: Annals of Oncology (2016)
Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.
Authors: Genevieve Gallagher, Donna E. Hogge, Thomas J. Nevill, Stephen H. Nantel, Michael J. Barnett, John D. Shepherd, Heather J. Sutherland, Cynthia L. Toze, Clayton A. Smith, Julye C. Lavoie, Kevin W. Song, Donna L. Forrest
Journal: Blood (2005)
Diabetes Impairs Bone Marrow Microenvironment Affecting Progenitor Cell Number, Mobilization and Engraftment in Humans.
Authors: Vittorio Rizzoli, Elena Masselli, Lucia Prezioso, Francesca Ferraro, Elisa Lodi-Rizzini, Marcellina Mangoni, Gallia Graiani, Caterina Frati, Gaia Spinetti, Carlotta Reni, Costanza Emanueli, Costanza Emanueli, Paolo Madeddu, Federico Quaini
Journal: Blood (2009)
Autologous Stem Cell Transplantation (ASCT) in 121 Acute Myeloid Leukemias (AML): A Single Center Experience From 1988 to 2010
Authors: Carmen Montes-Gaisan, Amalia Cuesta, Susana Herraez, German Perez, Guillermo Martin, Arancha Bermudez, Andres Insunza, Carlos Richard, Eulogio Conde, Arturo Iriondo
Journal: Blood (2011)
STMC-37. S100A4 IS A CRITICAL REGULATOR OF STEMNESS AND THE MESENCHYMAL PHENOTYPE IN GBMS
Authors: Kin-hoe Chow, Hee Jeong Park, Joshy George, Andrew Gallup, Stephanie Wood, Keiko Yamamoto, Eric Neilson, Joel Graber, Dennis Steindler, Kyuson Yun
Journal: Neuro-Oncology (2016)

Accumulating evidence indicates that cellular stresses such as chemotherapy, radiation treatment, or hypoxic and acidic microenvironments can either select for or induce cellular changes that confer GBM cells with more stem cell-like or mesenchymal phenotypes. The mesenchymal phenotype is associated with aggressiveness and tumor recurrence in GBMs and stemness in other tumors. In addition, hypoxia and acidosis have been shown to increase the number of tumor initiating cells (TICs) in human GBM cultures, suggesting that elucidating mechanisms that regulate stemness and mesenchymal transition is critical for improving GBM treatment and care. Here we report that S100A4 is a critical regulator of stemness and the mesenchymal phenotype in GBMs. First, we show that S100a4 is a novel marker and a critical regulator of GBM TICs. Using mouse models and patient derived GBM tumorspheres, we show that S100a4 expression is enriched in TICs and that S100a4 function is critical for self-renewal of these cells. Furthermore, selective ablation of S100a4+ cells murine gliomas in vivo is sufficient to block tumor growth. Second, we show that human GBM tumorspheres cultured in low pH induce S100A4 expression and acquire the mesenchymal phenotype. Interestingly, S100A4 knockdown suppresses expression of key epithelial-mesenchymal transition (EMT) regulators, such as SNAIL2, ZEB1, and TGFb1. Importantly, acidosis-induced mesenchymal phenotype requires S100A4 function. Consistently, S100A4 expression is strongly associated with the mesenchymal subtype of GBM, and S100A4 is an independent prognostic indicator for the mesenchymal subtype GBM patient survival. In summary, we show that S100A4 is a novel marker and a regulator of GBM TICs and that it plays a critical role in promoting mesenchymal and stem cell phenotypes in GBMs, directly linking the two cellular phenotypes associated with therapy resistance and tumor recurrence.
Modeling the Genetic Regulation of Cancer Metabolism: Interplay between Glycolysis and Oxidative Phosphorylation
Authors: Linglin Yu, Mingyang Lu, Dongya Jia, Jianpeng Ma, Eshel Ben-Jacob, Herbert Levine, Benny Abraham Kaipparettu, José N. Onuchic
Journal: Cancer Research (2017)

Abnormal metabolism is a hallmark of cancer, yet its regulation remains poorly understood. Cancer cells were considered to utilize primarily glycolysis for ATP production, referred to as the Warburg effect. However, recent evidence suggests that oxidative phosphorylation (OXPHOS) plays a crucial role during cancer progression. Here we utilized a systems biology approach to decipher the regulatory principle of glycolysis and OXPHOS. Integrating information from literature, we constructed a regulatory network of genes and metabolites, from which we extracted a core circuit containing HIF-1, AMPK, and ROS. Our circuit analysis showed that while normal cells have an oxidative state and a glycolytic state, cancer cells can access a hybrid state with both metabolic modes coexisting. This was due to higher ROS production and/or oncogene activation, such as RAS, MYC, and c-SRC. Guided by the model, we developed two signatures consisting of AMPK and HIF-1 downstream genes, respectively, to quantify the activity of glycolysis and OXPHOS. By applying the AMPK and HIF-1 signatures to The Cancer Genome Atlas patient transcriptomics data of multiple cancer types and single-cell RNA-seq data of lung adenocarcinoma, we confirmed an anticorrelation between AMPK and HIF-1 activities and the association of metabolic states with oncogenes. We propose that the hybrid phenotype contributes to metabolic plasticity, allowing cancer cells to adapt to various microenvironments. Using model simulations, our theoretical framework of metabolism can serve as a platform to decode cancer metabolic plasticity and design cancer therapies targeting metabolism. Cancer Res; 77(7); 1564-74. ©2017 AACR.
Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
Authors: Xiao Liu, Tica Pichulik, Olaf-Oliver Wolz, Truong-Minh Dang, Andrea Stutz, Carly Dillen, Magno Delmiro Garcia, Helene Kraus, Sabine Dickhöfer, Ellen Daiber, Lisa Münzenmayer, Silke Wahl, Nikolaus Rieber, Jasmin Kümmerle-Deschner, Amir Yazdi, Mirita Franz-Wachtel, Boris Macek, Markus Radsak, Sebastian Vogel, Berit Schulte, Juliane Sarah Walz, Dominik Hartl, Eicke Latz, Stephan Stilgenbauer, Bodo Grimbacher, Lloyd Miller, Cornelia Brunner, Christiane Wolz, Alexander N.R. Weber
Journal: Journal of Allergy and Clinical Immunology (2017)
Deferiprone Versus Sequential Deferiprone-Deferoxamine Treatment in Thalassemia Major: A Five Years Multicenter Randomized Clinical Trial under the Auspices of the Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE).
Authors: Aurelio Maggio, Marcello Capra, Liana Cuccia, Francesco Gagliardotto, Carmelo Magnano, Vincenzo Caruso, Calogera Gerardi, Maria G. Friscia, Crocetta Argento, Saveria Campisi, Francesco Cantella, Paolo Cianciulli, Francesca Commendatore, Domenico G. D’Ascola, Carmelo Fidone, Aldo Filosa, Alberto Fragasso, Marika Galati, Gaetano Giuffrida, Roberto Giugno, Turi Lombardo, Roberto Malizia, Anna Meo, Michele Rizzo, Gaetano Roccamo, Maria A. Romeo, Pietro Violi, Alessia Pepe, Gennaro D’Amico, Alberto Morabito
Journal: Blood (2007)
A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study
Authors: Thomas Prebet, Zhuoxin Sun, Rhett Ketterling, Gary Hicks, C.L. Beach, Peter L. Greenberg, Elisabeth Paietta, Magdalena Czader, Janice Gabrilove, Harry P Erba, Martin S. Tallman, Steven D. Gore
Journal: Blood (2010)
Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence
Authors: Carlos De las Cuevas, Jose de Leon
Journal: Psychotherapy and Psychosomatics (2017)

There is little current interest in research into patients' attitudes toward medications. In the 1960s, psychiatric researchers including Uhlenhuth, Rickels and Covi focused on this area, but this research topic needs to be revived in the 21st century. The Health Belief Model may hold potential for doing this. This model was initially developed by 2 health psychologists, Rosenstock and Becker, to explain why patients did not follow medical interventions. The application of this model to study medication adherence in psychiatric outpatients has provided multiple findings including the conclusions that adherence is associated with: (1) the balance between internal and external health control beliefs, (2) psychological reactance, (3) patients' attitudes toward prescribed drug treatment in general and (4) the balance between the necessity of taking medications versus the concerns derived from adverse drug reactions (ADRs). Poor adherence is associated with several cognitive styles of patients, including: (1) high internal and external health control beliefs (patients who feel that their health is controlled both by external factors and their own beliefs), (2) higher psychological reactance, (3) pharmacophobia (present in 1/6 patients) and (4) skepticism about medications (a high concern for ADRs and a low belief in the necessity of taking medications). All of these findings suggest that shared decision-making is particularly important in fostering adherence in psychiatric patients. Two wider applications of this article can be made: (1) opening psychiatry to advances in clinical psychology and (2) expanding studies on attitudes toward medications to other medical disciplines.
Myelodysplastic syndromes developing after imatinib therapy for GIST
Authors: P. Spadaro, M. Ingemi, V. Pitini, C. Arrigo, H. Soto Parra
Journal: Journal of Clinical Oncology (2009)

10532 Background: Imatinib mesylate 400 mg a day is the standard treatment for patients (pts.) who have advanced or metastatic gastrointestinal stromal tumor (GIST) even if different kit and PDGFRA mutations have a marked impact on the outcome of pts.; briefly, pts. with exon 9 mutations fared worse than those who had exon 11 mutations and both types of pts. did better than those with wild type genotype. Previously, we had detected clonal chromosomal abnormalities in the bone marrow of GIST pts. who developed a myelodysplastic syndrome during treatment with imatinib, so we performed a systematic study in a series of male and female GIST pts. during treatment with imatinib. Methods: Between January 2007 and December 2008, bone marrow samples for morphologic analysis, FISH and classical cytogenetics were obtained from 49 pts. (30 male; 19 female, mean age 62) with unresectable or metastatic GIST before and during treatment with 400 mg/d of imatinib. For pts. with progressive disease (15 pts.) or exon 9 mutant disease (5 pts.), imatinib 800 mg a day was scheduled. All pathologic material was reviewed to identify pts. with MDS or AML according to the WHO classification. Interphase and metaphase preparations were done according to the standard protocol. Results: At the time of analyses, all pts. were evaluable. Ten patients experienced anemia of grade 3–4 while five pts. developed granulocytopenia of grade 3–4. Eight pts. acquired cytogenetic chromosomal abnormalities in their bone marrow. A trisomy 8 was detectable in seven pts. even if, curiously, in four of these pts. this come and went on repeated sampling without any apparent clinical effect, three pts. developed an MDS (two refractory cytopenias with multilineage dysplasia, and one refractory cytopenia with multilineage dysplasia and ringed sideroblast). One patient developed a RAEB-1 with monosomy 7 which rapidly transformed into AML. Conclusions: During therapy with imatinib some pts. with GIST developed chromosomal abnormalities. Although, these occurrences are rare, the findings highlight the need for close monitoring of pts. with GIST treated with imatinib. No significant financial relationships to disclose.
Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.
Authors: Magdalini Migkou, Evangelos Terpos, Dimitrios Christoulas, Maria Gavriatopoulou, Georgios Boutsikas, Maria Gkotzamanidou, Marina Iakovaki, Efstathios Kastritis, Athanasios Papatheodorou, Meletios A. Dimopoulos
Journal: Blood (2009)
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial
Authors: M. Tiseo, L. Boni, F. Ambrosio, A. Camerini, E. Baldini, S. Cinieri, F. Zanelli, E. Defraia, M. Brighenti, L. Crinò, C. Dazzi, C. Tibaldi, G.M. Turolla, V. D'Alessandro, N. Zilembo, A.R. Trolese, F. Grossi, F. Riccardi, A. Ardizzoni
Journal: Annals of Oncology (2016)
MicroRNA‐191 acts as a tumor promoter by modulating the TET1–p53 pathway in intrahepatic cholangiocarcinoma
Authors: Hao Li, Zun‐Qiang Zhou, Zhang‐Ru Yang, Da‐Nian Tong, Jiao Guan, Bao‐Jie Shi, Jia Nie, Xian‐Ting Ding, Bin Li, Guang‐Wen Zhou, Zheng‐Yun Zhang
Journal: Hepatology (2017)

Current treatment of intrahepatic cholangiocarcinoma (ICC) remains ineffective because knowledge of ICC carcinogenesis is unclear. Increasing evidence suggests that microRNAs (miRNAs), including miR‐191, play an important role in tumorigenesis; but expression and biological functions of miR‐191 in ICC remain to be established. This study investigated the functions and underlying mechanisms of miR‐191 in ICC. ICC miRNA profiles were generated in five pairs of ICC and matched to normal bile duct tissues by next‐generation sequencing technology; ICC miRNA profiles were verified in 18 pairs of ICC tissues and normal bile duct tissues by quantitative RT‐PCR. The miR‐191‐associated mechanisms in ICC were investigated in vitro and in vivo , and clinical outcomes associated with miR‐191 were correlated in 84 patients. Our results showed that miR‐191 expression was significantly increased in ICC compared with the adjacent normal bile duct tissues ( P &lt; 0.001). Overexpression of miR‐191 promoted proliferation, invasion, and migration of cholangiocarcinoma cells in vitro and in vivo . The elevated miR‐191 expression reduced the expression level of ten‐eleven translocation 1 (TET1)—a direct target gene of miR‐191 in ICC, which catalyzes demethylation. The reduced TET1 expression level allowed the methylated CpG‐rich regions at the p53 gene transcription start site stay methylated, leading to reduced p53 expression level, which compromises p53's anticancer vigor. Finally, miR‐191 was found to be an independent risk factor for poor prognosis in patients with ICC (overall survival, hazard ratio = 3.742, 95% confidence interval 2.080‐6.733, P &lt; 0.001; disease‐free survival, hazard ratio = 2.331, 95% confidence interval 1.346‐4.037, P = 0.003). Conclusion: Our results suggest that overexpressed miR‐191 is associated with ICC progression through the miR‐191/TET1/p53 pathway. (H epatology 2017;66:136–151).
The Human Blood Hierarchy Is Shaped By Distinct Progenitor Lineages Across Development
Authors: Sasan Zandi, Faiyaz Notta, John E. Dick, Naoya Takayama, Stephanie M Dobson, Olga I Gan, Gavin Wilson, Kerstin Kaufmann, Jessica McLeod, Elisa Laurenti, Cyrille Dunant, Mcpherson John, Lincoln Stein, Yigal Dror
Journal: Blood (2015)
Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)
Authors: R. Riechelmann, V. Srimuninnimit, P. Kavan, M. Di Bartolomeo, E. Maiello, I. Cicin, H. Kröning, P. Garcia-Alfonso, I. Chau, C. Fernández-Martos, M. Ter-Ovanesov, M. Peeters, P. Picard, R. Bordonaro
Journal: Annals of Oncology (2016)
PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: J.S. de Bono, A.-C. Hardy-Bessard, C.S. Kim, L. Géczi, D. Ford, L. Mourey, J. Carles, P. Parente, A. Font, G. Kacsó, M. Chadjaa, W. Zhang, J. Bernard, M. Eisenberger
Journal: Annals of Oncology (2016)
Shortlisted teams announced for The BMJ Awards 2017
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

Anyone in any doubt that clinicians are pushing the boundaries of innovation despite the pressures engulfing the NHS need look no further than The BMJ Awards finalists for 2017. The shortlisted entries represent inspiring and pioneering teamwork with patient outcomes at their core.

The awards, now in their ninth year, attracted 290 entries this year with three new categories included for 2017: imaging, surgery, and mental health.

The winners will be announced on 4 May at the Park Plaza Westminster Bridge, London.

Shortlisted in …
Shared Decision Making for Children With Trisomy 13 and 18
Authors: Jeffrey P. Brosco, Chris Feudtner
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal